Prelude Therapeutics (PRLD) Cash from Investing Activities (2019 - 2026)

Prelude Therapeutics has reported Cash from Investing Activities for 8 years, with the latest figure at $8.5 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 86.33% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$228000.0 (down 100.19% YoY) and the FY2025 annual result came in at $53.5 million, down 40.73% from the prior year.
• Cash from Investing Activities grew to $8.5 million in Q1 2026 per PRLD's latest filing, from -$60.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $62.2 million in Q1 2025 and troughed at -$75.4 million in Q2 2023.
• A 5-year average of $11.7 million and a median of $15.0 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities surged 15474.28% in 2022, then plunged 372.8% in 2025.
• Over 5 years, Cash from Investing Activities stood at $1.4 million in 2022, then soared by 470.92% to $7.7 million in 2023, then jumped by 185.91% to $22.1 million in 2024, then slumped by 372.8% to -$60.3 million in 2025, then surged by 114.09% to $8.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $8.5 million, -$60.3 million, and $40.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.